Drug Profile
Apomorphine intranasal - Nastech Pharmaceutical Company
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Erectile dysfunction; Female sexual dysfunction
Most Recent Events
- 14 Aug 2006 No development reported - Phase-II for Erectile dysfunction in USA (Intranasal)
- 14 Aug 2006 No development reported - Phase-II for Female sexual dysfunction in USA (Intranasal)
- 28 Apr 2004 Nastech has completed the phase II Maximum Tolerated Dose trial in Erectile dysfunction